SCHEMBL1647432

SCHEMBL1647432

O=C(OCc1ccccc1)c1ccc(OCc2ccccc2)c(C(=O)OCc2ccccc2)c1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.58
KMT2A Q03164 2/20 0.58
SLC6A2 P23975 1/20 0.58
SLC6A3 Q01959 1/20 0.58
LMNA P02545 2/20 0.58
ALDH1A1 P00352 4/20 0.55
RAB9A P51151 4/20 0.55
NPC1 O15118 3/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
MAPT P10636 2/20 0.55
HTT P42858 1/20 0.55
FOLH1 Q04609 1/20 0.52
HPGD P15428 2/20 0.51
PARP1 P09874 1/20 0.51
POLB P06746 2/20 0.51
KDM4E B2RXH2 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
MEN1 O00255 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1316640 0.93 ALDH1A1 (0.56) TDP1KMT2ASLC6A2SLC6A3LMNA
SCHEMBL17747123 0.90 MAOB (0.55) TDP1KMT2ASLC6A2SLC6A3LMNA
SCHEMBL17747097 0.89 SMN1; SMN2 (0.51) TDP1KMT2ASLC6A2SLC6A3LMNA
SCHEMBL30141105 0.88 KMT2A (0.62) TDP1KMT2ASLC6A2SLC6A3LMNA
SCHEMBL3960907 0.88 KMT2A (0.62) TDP1KMT2ASLC6A2SLC6A3LMNA
SCHEMBL17747100 0.88 SMN1; SMN2 (0.50) TDP1KMT2ASLC6A2SLC6A3LMNA
SCHEMBL1316171 0.88 MAPT (0.53) TDP1KMT2ASLC6A2SLC6A3LMNA
SCHEMBL5332908 0.87 KMT2A (0.57) TDP1KMT2ASLC6A2SLC6A3LMNA
SCHEMBL23809724 0.86 ALDH1A1 (0.62) TDP1KMT2ASLC6A2SLC6A3LMNA
SCHEMBL9203039 0.86 ALDH1A1 (0.49) TDP1KMT2ASLC6A2SLC6A3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2483254-B1 NOVEL COMPOUNDS GLAXO GROUP LTD (GB) 2014-08-13 EP disclosed
US-8778939-B2 Compounds GLAXO GROUP LIMITED (GB) 2014-07-15 US disclosed
EP-2483254-A1 NOVEL COMPOUNDS Glaxo Group Limited (GB) 2012-08-08 EP disclosed
US-20120184553-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2012-07-19 US disclosed
WO-2011038572-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2011-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184553-A1 NOVEL COMPOUNDS LRRK2, PARK7, PINK1 TDP1 705/4885KMT2A 2336/4885SLC6A2 2705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.